Previous close | 1.9200 |
Open | 1.9800 |
Bid | 1.4700 x 200 |
Ask | 2.3600 x 200 |
Day's range | 1.8100 - 2.0600 |
52-week range | 1.6200 - 44.0000 |
Volume | |
Avg. volume | 2,093,950 |
Market cap | 8.972M |
Beta (5Y monthly) | 0.20 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Longeveron Inc (NASDAQ:LGVN), a biotechnology company specializing in the development of cellular therapies for aging-related and life-threatening conditions, has reported an insider purchase by a high-level executive.
Longeveron ( NASDAQ:LGVN ) Full Year 2023 Results Key Financial Results Net loss: US$22.2m (loss widened by 18% from FY...
Longeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Call Transcript February 27, 2024 Longeveron Inc. misses on earnings expectations. Reported EPS is $-0.25 EPS, expectations were $-0.21. FDS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, good afternoon, and […]